FULC - Pre Run-Up Biotech Catalyst Play

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

On October 10, 2024 there will be Phase 3 Data released - i expect a pre run up into the catalyst.

Breakout Zone: $9.50

Action: If the stock breaks above this area with strong volume, it might signal a continuation of the upward trend.

Overall Market Sentiment:
Currently, the market seems to be in a correction phase. It’s crucial to consider this sentiment when making trading decisions.

Resistance Points:

$9.50
$11.30
$12.50

Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains.

Trading Strategy:

Take Profit (TP): Set a target at $14.20 maybe even 21.00 is possible if catalyst will be positive.

Stop Loss (SL): Set at under $7.90 to mitigate potential losses.

Chart Analysis:
Please refer to the attached chart for detailed analysis of price trends and movements.

Trading Advisory:
Exercise caution and consider market conditions and your own risk tolerance when trading. It's advisable to conduct comprehensive research or consult with a financial advisor before engaging in trading activities.

Disclaimer: This content is for informational purposes only and should not be considered financial advice.